PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
February 19, 2026Clinical Cancer Research2 citations

Evaluating Adjuvant Chemotherapy with Ovarian Function Suppression and Endocrine Therapy

Abstract PS5-07-04: NRG-BR009: A phase III trial evaluating addition of adjuvant chemotherapy to Ovarian Function Suppression + Endocrine Therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer and recurrence score ≤25 (OFSET)

View Full Paper
Ask AI
Bookmark
Share

Authors

SSS. M. SwainGTG. TangSPS. L. Puhalla

Discussion

Loading...

Member takes

Overview

Phase III trial evaluates invasive breast cancer-free survival in premenopausal women, indicating potential benefits of combined therapies.

Key Points

  • This trial aims to determine if adding adjuvant chemotherapy to ovarian function suppression and endocrine therapy increases breast cancer-free survival in specific premenopausal women.
  • Phase III clinical trial
  • Randomized premenopausal women with early-stage HR+/HER2- breast cancer to either OFS+ET or ACT+OFS+ET
  • Patients categorized by recurrence score and nodal status
  • Health-related quality of life assessments included
  • Sample collection for future research
  • Estimated 5-year invasive breast cancer-free survival is 92.3% for patients on ACT+OFS+ET
  • Estimated 95% for pN0 patients on the ACT arm
  • 380 invasive breast cancer-free survival events required for definitive analysis
  • 292 out of 3960 patients have been accrued as of now
  • Majority received monthly dosing of goserelin or leuprolide for ovarian function suppression

Cite This Study

Swain et al. (2026) studied this question.

synapsesocial.com/papers/6996a8efecb39a600b3f0356https://doi.org/10.1158/1557-3265.sabcs25-ps5-07-04
View Full Paper
Ask AI
Bookmark
Share